ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022
May 18, 2017 10:31 am UTC| Business
- OBE022 is ObsEva's potential first-in-class, oral and selective PGF2alpha receptor antagonist for the treatment of preterm labor - Geneva, Switzerland and Boston, MA - 18 May 2017 - ObsEva SA (Nasdaq: OBSV), a...
The Bon-Ton Stores, Inc. Reports First Quarter Fiscal 2017 Results
May 18, 2017 10:31 am UTC| Business
YORK, Pa., May 18, 2017 -- The Bon-Ton Stores, Inc. (NASDAQ:BONT) today reported operating results for its fiscal first quarter ended April 29, 2017. Results for the First Quarter Ended April 29, 2017 Comparable...
The Bon-Ton Stores, Inc. Reports First Quarter Fiscal 2017 Results
May 18, 2017 10:30 am UTC| Business
YORK, Pa., May 18, 2017 -- The Bon-Ton Stores, Inc. (NASDAQ:BONT) today reported operating results for its fiscal first quarter ended April 29, 2017. Results for the First Quarter Ended April 29, 2017 Comparable...
May 18, 2017 10:05 am UTC| Business
NEW YORK, May 18, 2017 -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that clinical abstracts featuring TG-1101 and TGR-1202 have been selected for presentation at the upcoming 22nd European Hematology...
May 18, 2017 10:03 am UTC| Business
Path Toward Submission for Accelerated Approval Tazemetostat Demonstrates Clinically Meaningful Activity in Epithelioid Sarcoma; Interim Phase 2 Epithelioid Sarcoma and Synovial Sarcoma Data to be Presented at ASCO ...
May 18, 2017 10:03 am UTC| Business
Path Toward Submission for Accelerated Approval Tazemetostat Demonstrates Clinically Meaningful Activity in Epithelioid Sarcoma; Interim Phase 2 Epithelioid Sarcoma and Synovial Sarcoma Data to be Presented at ASCO ...
May 18, 2017 10:03 am UTC| Business
Path Toward Submission for Accelerated Approval Tazemetostat Demonstrates Clinically Meaningful Activity in Epithelioid Sarcoma; Interim Phase 2 Epithelioid Sarcoma and Synovial Sarcoma Data to be Presented at ASCO ...